

## **Galmed Pharmaceuticals to Participate in Investor Conferences in March**

TEL AVIV, Israel, Mar. 2, 2018 /[PRNewswire](#)/ -- Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of the liver-targeted SCD1 modulator Aramchol™, a once-daily, oral therapy for the treatment of nonalcoholic steatohepatitis, or NASH and other liver diseases, announced today that its senior management will provide a corporate update in upcoming investor conferences, including the Roth 30th Annual Conference, the H.C. Wainwright 2nd Annual NASH Investor Conference and the Oppenheimer 28th Annual Healthcare Conference.

### **Roth 30th Annual Conference:**

Date: Monday, March 12

Time: 2:30 pm Pacific Time

Location: GREEN - SALON 3, The Ritz-Carlton, Laguna Niguel, CA

### **H.C. Wainwright 2nd Annual NASH Investor Conference:**

Date: Monday, March 19

Time: 10:00 am Eastern Time

Location: The St. Regis Hotel, New York, NY

### **Oppenheimer 28th Annual Healthcare Conference:**

Date: Tuesday, March 20

Time: 09:45 am Eastern Time

Location: Track 2 room, The Westin New York Grand Central, New York City

### **About Aramchol™ and Non-alcoholic Steatohepatitis (NASH)**

Aramchol™ (arachidyl amido cholanoic acid) is a novel fatty acid bile acid conjugate, inducing beneficial modulation of intra-hepatic lipid metabolism. Aramchol's ability to modulate hepatic lipid metabolism was discovered and validated in animal models, demonstrating down regulation of the three key pathologies of NASH: steatosis, inflammation and fibrosis. The effect of Aramchol™ on fibrosis is mediated by down regulation of steatosis and directly on human collagen producing cells. Aramchol™ has been granted Fast Track designation status by the FDA for the treatment of NASH.

NASH is an emerging world crisis impacting an estimated 3% to 5% of the U.S. population and an estimated 2% to 4% globally. It is the fastest growing cause of liver cancer and liver transplantation in the U.S. due to the rise in obesity. NASH is the progressive form of non-alcoholic fatty liver disease that can lead to cardiovascular disease, cirrhosis, liver cancer and end-stage liver disease related mortality.

### ***About Galmed Pharmaceuticals Ltd.***

Galmed is a clinical-stage biopharmaceutical company focused on the development of Aramchol™, a first in class, novel, once-daily, oral therapy for the treatment of NASH for variable populations, as well as other liver associated disorders. Galmed is currently conducting the ARREST Study, a multicenter, randomized, double-blind, placebo-controlled Phase 2b clinical study designed to evaluate the efficacy and safety of Aramchol™ in subjects with NASH, who are overweight or obese, and who are pre-diabetic or type-II-diabetic. More information about the ARREST Study may be found on ClinicalTrials.gov identifier: NCT02279524.

SOURCE Galmed Pharmaceuticals Ltd.

For further information: Bob Yedid, LifeSci Advisors, LLC, +1-646-597-6979, [Bob@LifeSciAdvisors.com](mailto:Bob@LifeSciAdvisors.com).  
Guy Nehemya, VP Operations, Galmed Pharmaceuticals Ltd. [guy@galmedpharma.com](mailto:guy@galmedpharma.com)

---

Additional assets available online: [Photos \(1\)](#)

<https://galmedpharma.investorroom.com/2018-03-02-Galmed-Pharmaceuticals-to-Participate-in-Investor-Conferences-in-March>